This segment focuses on the research and development of small molecule therapeutics for immune-mediated diseases. The primary focus is on KZR-616, a selective immunoproteasome inhibitor, currently in Phase 2 clinical trials for lupus nephritis, dermatomyositis, and polymyositis, and Phase 1b trials in systemic lupus erythematosus and lupus nephritis. Research and development activities include preclinical studies, clinical trial management, and regulatory submissions. The company utilizes advanced drug discovery techniques and clinical trial methodologies to identify and develop effective treatments. The goal is to improve the lives of patients suffering from autoimmune diseases by targeting the underlying mechanisms of these conditions. Market positioning is based on addressing unmet medical needs in the autoimmune space. Future opportunities include expanding the clinical trials for KZR-616 and exploring other indications. Regulatory and clinical aspects involve obtaining FDA approval and ensuring patient safety. Partnerships and collaborations are essential for clinical trial execution and commercialization.

This segment is dedicated to the development of novel small molecule therapeutics for cancer treatment. The company's preclinical product, KZR-TBD, is being developed for oncology applications. Research and development activities include preclinical studies, target identification, and drug candidate optimization. The company employs advanced technologies and methodologies in drug discovery and development, including molecular biology and medicinal chemistry. The therapeutic areas covered include various types of cancer, with the aim of improving patient outcomes and survival rates. Market positioning is based on developing innovative cancer treatments. Future opportunities include advancing KZR-TBD through preclinical and clinical development. Regulatory and clinical aspects involve obtaining necessary approvals for clinical trials and commercialization. Partnerships and collaborations may be pursued to accelerate the development and commercialization of oncology products.